- citati u SCIndeksu: 0
- citati u CrossRef-u:0
- citati u Google Scholaru:[
 ]
- posete u poslednjih 30 dana:6
- preuzimanja u poslednjih 30 dana:5
|
|
|
2021, vol. 24, br. 94, str. 7-16
|
|
Istraživanje dokaza eksaptacije u kliničkim istraživanjima u kreiranju farmaceutskih inovacija
Study of exaptation evidence in clinical research for delivering pharmaceutical innovation
Sažetak
Eksaptacija je proces koji se odlikuje evolucijom karakteristika artefakta i evolucijom za druge upotrebe koji je kasnije prihvaćen kao njihova nova uloga. U farmaceutskoj industriji inovacije imaju visok potencijal u pogledu konkurentske prednosti i dobiti, ali su takođe povezane sa visokim rizicima povezanim sa troškovima, vremenom i neizvesnošću. Da bi umanjili rizike, kompanije često biraju strategiju eksaptacije u smislu ponovnog razvoja hemijskih jedinjenja za upotrebu kod drugih oboljenja. Namera ovog istraživanja je da pruži analizu i kvantifikaciju (merenje) broja lekova (molekula) koji su "eksaptirani" kroz proces repozicioniranja lekova. Rezultati ukazuju da smo na nivou od 6098 kliničkih studija, faza I, primetili ukupno 659 lekova / supstanci (~ 11%) koji su korišćeni u više kliničkih istraživanja za istu ili različitu indikaciju koja pokazuje nivo upotrebe eksaptacije u kliničkim istraživanjima.
Abstract
Exaptation is a process that is characterized by the evolution of characteristics, its evolution for other usages, and later coopted for their current role. In the pharmaceutical industry, innovations have high potential in terms of competitive advantage and profit but are also connected with high risks associated with costs, time, and uncertainty. To minimize risks, companies frequently choose the strategy of exaptation in terms of redeveloping compounds for use in a different disease. The intention of this research is to provide analysis and quantification (measurement) of drugs that have been exaptated through the process of drug reposition. Results indicate that on level of 6098 clinical studies Phase I, we have observed a total of 659 drugs/substances (~11%) that have been used in more than one clinical research for the same or different indication showing the level of exaptation use in clinical research.
|
|
|
|
Reference
|
|
|
*** ABScience. Available at: https://arxiv.org/abs/1905.11659, Accessed on 01/02/2021
|
|
|
*** ICD classification. Available at: https://icd.who.int/browse10/2019/ en, Accessed on 01/02/2021
|
|
  
|
Andriani, P., Ali, A., Mastrogiorgio, M. (2017) Measuring exaptation and its impact on innovation, search, and problem-solving. Organization Science, 28(2), 320-338
|
|
|
Arthur, B., Polak, W. (2006) The evolution of technology within a simple computer model. Complexity, Volume 11, Issue 5. Willey
|
|
|
Astin, J.W., et al. (2017) Methods in cell biology. Volume 138, Pages 31-60, Chapter 2
|
|
|
Barlas, Y., Carpenter, S. (1990) Philosophical roots of model validation: Two paradigms. System Dynamics Review, Vol. 6, No. 2, pp. 148-166
|
|
|
Dew, N., Sarasvathy, S.D. (2016) Exaptation and niche construction: Behavioral insights for an evolutionary theory. Industrial and Corporate Change, Volume 25, Issue 1, February, Pages 167-179
|
|
1
|
Dimasi, J.A., Grabowski, H.G., Hansen, R.W. (2016) Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47: 20-33
|
|
|
Ferreira,, et al. (2020) Quantifying exaptation in scientific evolution: Physics and society. Available at: https://arxiv.org/pdf/2002.08144.pdf, Accessed on 10/02/2021
|
|
|
Gabora, L., et al. (2011) Progress in biophysics and molecular biology. Volume 113, Issue 1, September 2013, Pages 108-116
|
|
|
Gould, S., Vrba, E. (1982) Exaptation: A missing term in the science of form. Paleobiology, 8(1), 4-15
|
|
|
Mazzucato, M., Tancioni, M. (2012) R&D, patents and stock return volatility. Journal of Evolutionary Economics, 22: 811-832
|
|
|
Medina, L., et al. (2015) Epigenetic technological applications. DNA Methyltransferase Inhibitors for Cancer Therapy, Pages 265-290. Chapter 13
|
|
|
Pedersen, K., et al. (2000) Validating design methods & research: The validation square. u: Proceedings of ASME design engineering technical conferences. September 10-14, Baltimore, MD
|
|
|
Pizzorno,, et al. (2019) Drug repurposing approaches for the treatment of influenza viral infection: Reviving old drugs to fight against a long-lived enemy. Frontiers in Immunology, Frontiers, 10. Available at:https://hal.archives-ouvertes.fr/hal-02322449/document, Accessed on 01/02/2021
|
|
|
Pizzorno, A., et al. (2019) Drug repurposing approaches for the treatment of influenza viral infection: Reviving old drugs to fight against a long-lived enemy. Frontiers in Immunology, Volume 10
|
|
|
Prata, W., et al. (2017) A critical look at innovation profile and its relationship with pharmaceutical industry. International Journal of Scientific Research and Management (IJSRM), Volume 5. Issue. 07. Pp. 5934-5948
|
|
|
|
|